A small group of subjects with NASH had decreases in markers of hepatic fibrosis including TGF-β1, less activation of stellate cells, and histological improvement on liver biopsy after treatment with ARBs [41, 42]. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatohepatitis.